Núcleo de Pesquisas de Produtos Naturais, UFRJ, 21941-971 Rio de Janeiro, RJ, Brazil.
Eur J Med Chem. 2013 May;63:523-30. doi: 10.1016/j.ejmech.2013.02.038. Epub 2013 Mar 7.
Continuing our screening program for novel anti-parasite compounds, we synthesized seven 1,4-naphthoquinones coupled to 1,2,3-triazoles, five nor-β-lapachone-based 1,2,3-triazoles and ten α-lapachone-based 1,2,3-triazoles. These and other naphthoquinonoid compounds were evaluated for their activity against promastigote forms of antimony-sensitive and -resistant strains of Leishmania infantum (syn. Leishmania chagasi) and Leishmania amazonensis. The toxicity of these compounds to mammalian cells was also examined. The substances were more potent than an antimonial drug, with IC50 values ranging from 1.0 to 50.7 μM. Nor-α-lapachone derivatives showed the highest antileishmanial activity, with selectivity indices in the range of 10-15. These compounds emerged as important leads for further investigation as antileishmanial agents. Additionally, one of these compounds exhibited cross-resistance in Sb-resistant Leishmania and could provide a molecular tool for investigating the multidrug resistance mechanisms in Leishmania parasites.
为了继续筛选新型抗寄生虫化合物,我们合成了七种与 1,2,3-三唑偶联的 1,4-萘醌、五种基于诺-β-拉帕醌的 1,2,3-三唑和十种基于 α-拉帕醌的 1,2,3-三唑。我们评估了这些萘醌类化合物以及其他化合物对锑敏感和耐药的婴儿利什曼原虫(即恰加斯利什曼原虫)和亚马逊利什曼原虫的前鞭毛体的活性。我们还研究了这些化合物对哺乳动物细胞的毒性。这些物质比锑剂更有效,IC50 值范围为 1.0 至 50.7 μM。诺-α-拉帕酮衍生物表现出最高的抗利什曼原虫活性,其选择性指数在 10-15 之间。这些化合物有望成为进一步研究的重要先导化合物,作为抗利什曼原虫药物。此外,其中一种化合物在耐药利什曼原虫中表现出交叉耐药性,可作为研究利什曼原虫多药耐药机制的分子工具。